Lynparza Dosing Schedule, Reductions, and Adjustments

Lynparza (olaparib) is dosed as 300 mg taken by mouth twice daily, using two 150-mg tablets each time, for a total daily intake of 600 mg. That standard dose applies across its approved uses in ovarian, breast, pancreatic, and prostate cancers, though individual patients frequently need adjustments based on side effects, kidney function, or other medications they take. Understanding how and when those adjustments happen, and why they generally do not compromise the drug’s effectiveness, matters for anyone starting or already on this therapy.

The Standard Dose and How to Take It

The recommended dose is two 150-mg tablets twice a day, roughly 12 hours apart, for a total of four tablets per day.¹ You can take them with or without food. A food-effect study found that eating slowed how quickly olaparib was absorbed and lowered peak blood levels by about 21%, but the total amount of drug that eventually reached the bloodstream stayed within acceptable limits.² In practice, this means food does not change how well the drug works over time, though some patients find that taking it with a meal or snack eases nausea.

Tablets should be swallowed whole, not crushed or chewed. Lynparza also comes in a 100-mg tablet size, which is used when the dose needs to be reduced. Having both the 150-mg and 100-mg tablet strengths available gives prescribers flexibility to hit the specific lower doses required in certain situations.

Capsules Versus Tablets Are Not Interchangeable

If you have encountered older prescribing information or discussion threads mentioning olaparib capsules, those referred to the original formulation that required patients to take sixteen 50-mg capsules every day. The tablet version replaced it, and the two formulations are not the same drug from a pharmacokinetic standpoint. The tablet has improved bioavailability, meaning more of the active drug reaches the bloodstream per milligram swallowed, so the tablet dose (300 mg twice daily) is lower than the old capsule dose (400 mg twice daily) while achieving comparable drug exposure.³

For anyone who was ever switched from capsules to tablets, the conversion was not milligram-for-milligram. A patient on the full capsule dose of 400 mg twice daily moved to 300 mg tablets twice daily. Those on a reduced capsule dose of 200 mg twice daily shifted to 250 mg tablets twice daily, and patients on 100 mg capsules twice daily moved to 200 mg tablets twice daily.⁴ In most countries, the capsule is no longer commercially available, so this mainly matters for understanding older data or if you come across leftover capsules. The key point: never assume the two formulations can be swapped one-for-one.

When and How the Dose Gets Reduced

Side effects are the most common reason patients end up on a lower dose. The standard step-down path for the tablet goes from 300 mg twice daily to 250 mg twice daily, and if needed, down again to 200 mg twice daily. If side effects remain unmanageable at 200 mg twice daily, the drug is usually stopped. These reductions are guided by blood counts and how you are feeling, and your oncology team will typically check both regularly, especially during the first few months.

The side effects that most often trigger dose changes are hematologic: low red blood cells (anemia), low platelets, and low white blood cells (neutropenia). Most adverse events seen in clinical trials were mild to moderate in severity.⁵ Fatigue and gastrointestinal symptoms like nausea also rank among the most common complaints. French expert consensus recommends pausing Lynparza for symptomatic or higher-grade blood count drops until labs improve to a milder level, then restarting at a reduced dose.⁶ For nausea, anti-nausea medications and small, frequent meals often help patients stay on therapy without needing a permanent dose cut.

Data from the SOLO1 trial, a large study of Lynparza in newly diagnosed ovarian cancer patients with BRCA mutations, found that most adverse events were manageable with supportive care or dose adjustments, and relatively few patients had to stop the drug entirely.⁷ This is reassuring: needing a dose reduction does not mean treatment has failed.

Dose Reductions Do Not Appear to Hurt Outcomes

One of the most useful findings for patients is that taking less than the full dose does not seem to undermine Lynparza’s cancer-fighting benefit. An analysis of the SOLO2 trial examined patients grouped by their relative dose intensity at 12 weeks. Those who received 90% or less of the planned dose had progression-free survival of about 34 months compared with about 14 months in the group that received more than 98% of the dose, and overall survival was statistically similar across all groups.⁸ The differences did not reach statistical significance, which means there was no detectable penalty for patients whose dose was lowered.

Real-world data tell a consistent story. A study of patients with recurrent ovarian cancer compared those on the standard dose with those who needed reductions. Median progression-free survival was 27 months in the full-dose group, 28 months in those with early reductions, and 32 months in those with later reductions. Overall survival was similarly comparable across groups.⁹ The authors concluded that a reduced dosing strategy is a viable option for patients experiencing side effects. This evidence is worth knowing because it can ease the anxiety of accepting a dose cut: staying on a lower dose you can tolerate is better than struggling through a dose that makes you feel miserable or dropping the drug altogether.

Drug Interactions That Change the Dose

Olaparib is processed in the body primarily through an enzyme pathway called CYP3A4. When another drug strongly inhibits that pathway, olaparib levels in the blood rise, effectively giving you an overdose at normal dosing. The fix is straightforward: if you must take a strong CYP3A4 inhibitor while on Lynparza tablets, the dose drops to 100 mg twice daily. For a moderate CYP3A4 inhibitor, the dose drops to 150 mg twice daily.¹⁰ Weak inhibitors of CYP3A4 do not require any dose change.¹¹

Common strong CYP3A4 inhibitors include certain antifungal drugs like itraconazole and ketoconazole, the antibiotic clarithromycin, and some HIV medications. Moderate inhibitors include fluconazole, erythromycin, and grapefruit juice in large amounts. These lists are not exhaustive, and your pharmacist or oncologist should review everything you take, including supplements and over-the-counter products, before and during Lynparza therapy.

On the other side, drugs that strongly or moderately induce CYP3A4, like rifampin, certain seizure medications, and St. John’s wort, speed up olaparib’s breakdown and can make it ineffective. The recommendation is to avoid strong and moderate CYP3A4 inducers entirely rather than try to compensate by raising the Lynparza dose.¹² If one of those inducers is medically necessary, the treatment team will typically look for a substitute that does not interact.

Adjustments for Kidney and Liver Function

Your kidneys and liver affect how quickly olaparib clears your body, and the dose adjustments are not symmetrical between the two organs.

For kidney impairment, mild disease (creatinine clearance roughly 51–80 mL/min) causes only a small bump in olaparib exposure that is not considered clinically meaningful, so no dose change is needed. Moderate kidney impairment (creatinine clearance roughly 31–50 mL/min) raises olaparib exposure by about 44%, enough to warrant careful monitoring and a dose reduction to 200 mg twice daily.¹³ There is limited data on severe renal impairment, so patients in that category are typically managed on a case-by-case basis with extra monitoring.

Liver impairment is more forgiving. A dedicated pharmacokinetic study found that patients with mild or moderate hepatic impairment showed no clinically significant changes in olaparib exposure compared to patients with normal liver function, and the safety profiles were similar. No dose reduction is needed for mild or moderate liver disease.¹⁴ Severe hepatic impairment has not been formally studied, so the drug is generally used with caution, if at all, in that setting.

How Long You Stay on Lynparza

Treatment duration depends on the clinical scenario. In the landmark SOLO1 trial, which studied Lynparza as maintenance therapy in newly diagnosed advanced ovarian cancer with a BRCA mutation, patients were randomized to receive olaparib or placebo for up to two years.¹⁵ That two-year cap became a widely adopted practice guideline for the first-line ovarian cancer maintenance setting. If cancer progresses during treatment, therapy is discontinued regardless of how long you have been on it.

In the recurrent ovarian cancer setting, and in pancreatic and prostate cancer indications, treatment typically continues until disease progression or unacceptable toxicity rather than being capped at a fixed duration. Practically, this means some patients stay on Lynparza for many months or even years. The SOLO2 trial, for example, followed patients for extended periods, and some remained on maintenance therapy well beyond the initial treatment window.

The distinction matters because a two-year limit is not a universal rule. If your oncologist recommends continuing beyond two years or stopping before two years, it reflects the specific indication, how the cancer is behaving, and the evolving evidence base.

Blood Count Monitoring in Practice

Complete blood counts are the backbone of Lynparza safety monitoring. Most centers check a baseline count before starting treatment, then repeat it monthly for the first several months before spacing to every two to three months in patients who are tolerating the drug well. Anemia is the hematologic side effect that gets the most attention. It tends to develop gradually over weeks rather than appearing overnight, and it is the most common reason for dose reductions in practice.

Expert opinion from a Canadian urology group has emphasized a proactive approach to anemia management in prostate cancer patients on PARP inhibitors: anticipate it, monitor for it consistently, and intervene early with supportive care or dose modification before it becomes debilitating.¹⁶ While this guidance focused on prostate cancer, the principle applies to all Lynparza indications. If your hemoglobin starts trending down, catching it early gives you and your treatment team more options, including supportive measures like iron supplementation or erythropoiesis-stimulating agents where appropriate, before you need to reduce the dose or pause treatment.

A rare but serious hematologic concern with prolonged PARP inhibitor use is myelodysplastic syndrome or acute myeloid leukemia. The absolute risk is low (in clinical trials, roughly 1–2% of patients), but it is the reason oncologists continue to monitor blood counts even in patients who have been on therapy for a long time and seem to be tolerating it without issue.

Dosing in Older Adults

Age alone does not trigger a different starting dose. A systematic review and meta-analysis of PARP inhibitor use in older ovarian cancer patients found that dose modification rates were broadly similar across age groups. Among patients pooled from eight prospective trials, about 47% of those younger than 65 required a dose reduction compared with roughly 45% of patients aged 65–69 and 48% of those aged 70–74. The outlier was patients 75 and older, where about 65% needed a reduction, though this difference was not statistically significant given the small sample size.¹⁷

Quality of life scores also did not differ significantly between older and younger patients in the SOLO2 trial, which suggests that older adults who need dose adjustments do not necessarily experience a worse treatment journey than younger patients who also need adjustments. The practical takeaway is that clinicians generally start older patients at 300 mg twice daily and monitor closely, stepping down if needed. There is no evidence that prophylactic dose reduction at the start improves outcomes or tolerability in this group, though patients over 75 warrant particularly close follow-up given the trend toward higher dose-modification rates.

Missed Doses and Timing Practicalities

If you miss a dose, the standard guidance is to skip it and take the next one at the scheduled time. Do not double up. The drug’s half-life is roughly 12 hours, which is why the twice-daily schedule keeps blood levels fairly steady. Taking two doses close together would spike levels unnecessarily and increase the chance of side effects without providing meaningful extra benefit.

Consistency matters, but perfection does not. As the dose-intensity data from SOLO2 and real-world studies show, patients who ended up receiving well under 100% of the planned dose due to interruptions or reductions did not fare worse in terms of cancer control. If life occasionally gets in the way of perfect timing, a few hours of variation is unlikely to matter. That said, something like an alarm on your phone can be a useful tool if you find yourself frequently forgetting. Taking both doses roughly 12 hours apart, such as morning and evening with meals, is the easiest pattern for most people to maintain.

Why Nausea Is Often Worse at First

Nausea is one of the most common early complaints and can be discouraging if you do not know that it tends to improve. In clinical trial populations, gastrointestinal side effects frequently peaked within the first few weeks and then settled.¹⁸ This pattern is common enough that many oncologists proactively prescribe anti-nausea medication during the initial weeks. If you are experiencing persistent nausea past the first month, that warrants a conversation with your care team about whether a dose reduction, a different anti-emetic strategy, or both might help.

Taking Lynparza with food rather than on an empty stomach is a practical strategy for managing nausea. While eating does slow absorption and lower the peak concentration modestly, it does not meaningfully change the total drug exposure, as noted in the food-effect study. Some patients also find that spacing the tablets slightly, taking one and then the second ten minutes later, can reduce the initial wave of queasiness, though this is anecdotal rather than studied in trials. The main thing to avoid is letting nausea push you into skipping doses entirely without telling your oncology team, since they have a toolkit of solutions they can offer before it comes to stopping the drug.